Medpace Q2 2026 slides: bookings surge 28%, guidance raised By Investing.com

Medpace Holdings reported Q2 2026 revenue of $707.3 million, up 17.2% year over year, citing growth from small biopharma clients and expansion in Metabolic and Oncology. The company said its net book-to-bill improved to 1.13x and that backlog metrics supported raising its 2026 revenue forecast, according to the report.

Biotech stocks rose to 52-week highs on July 22, 2026 after positive updates. Medpace (MEDP) jumped over 77% to $677.90 on Q2 results, with GAAP net income of $121.4M and revenue up 17% to $707M. Novocure (NVCR) gained 28% to $20.55 on Q2 net revenues of $183.6M. Eton (ETON) and Maravai (MRVI) also hit highs; Advanced Biomed (ADVB) rose 36% to $20.87.

Biotech gainers highlighted include Advanced Biomed (ADVB), up about 211% this week to $16.78, with no product sales and a recent SEC registration withdrawal. Novocure (NVCR) rose over 28% after Q2 results and raised 2026 revenue guidance to $710M-$725M. Medpace (MEDP) gained 14% on Q2 revenue of $707.3M and 2026 outlook. SciSparc (SPRC) and Agenus (AGEN) also rose; AgomAb (AGMB) gained on upcoming trial readouts.

Medpace (MEDP) reported Q2 FY2026 revenue of $707.3M, up 17.2% YoY, with net book-to-bill of 1.13. Net income rose 34.5% to $121.4M, EPS was $4.25, and operating cash flow was $162M. Backlog ended at $3.0B. FY2026 guidance raised to revenue $2.805–2.885B and EPS $17.25–$17.95.

Medpace Holdings (NASDAQ:MEDP) reported Q2 EPS of $4.25 vs $3.97 consensus and revenue of $707.33M vs $687.65M. YoY revenue rose 17.2% with 24.1% backlog conversion. Project backlog grew 4.9% to over $3.01B. The company raised FY2026 EPS to $17.25-$17.95 and revenue to $2.805B-$2.885B.

Medpace Holdings (MEDP) shares rose after it reported Q2 2026 results that beat expectations and issued full-year guidance above Street forecasts, according to the article. The move lifted sentiment in the contract research organization peer group, with CRO stocks also trading higher.